Por favor, use este identificador para citar o enlazar este ítem:
http://hdl.handle.net/10609/146755
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Muñoz Moreno, Jose Antonio | - |
dc.contributor.author | Carrillo Molina, Sara | - |
dc.contributor.author | Martínez Zalacaín, Ignacio | - |
dc.contributor.author | Miranda, Cristina | - |
dc.contributor.author | Manzardo, Christian | - |
dc.contributor.author | Coll, Pep | - |
dc.contributor.author | Meulbroek, Michael | - |
dc.contributor.author | Hanke, Thomas | - |
dc.contributor.author | Garolera, Maite | - |
dc.contributor.author | Miró, Josep M. | - |
dc.contributor.author | Brander, Christian | - |
dc.contributor.author | Clotet Sala, Bonaventura | - |
dc.contributor.author | Soriano-Mas, Carles | - |
dc.contributor.author | Molto, Jose | - |
dc.contributor.author | Mothe, Beatriz | - |
dc.contributor.author | BCN02-Neuro Substudy Group | - |
dc.contributor.other | Fundació Lluita Contra la SIDA i les Malalties Infeccioses (FLS) | - |
dc.contributor.other | Hospital Universitari Germans Trias i Pujol | - |
dc.contributor.other | Universitat Oberta de Catalunya. Estudis de Psicologia i Ciències de l'Educació | - |
dc.contributor.other | Institut d'Investigació Biomèdica de Bellvitge | - |
dc.contributor.other | Universitat de Barcelona (UB) | - |
dc.contributor.other | Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) | - |
dc.contributor.other | Projecte dels NOMS-Hispanosida | - |
dc.contributor.other | Institut de Recerca de la Sida (IrsiCaixa) | - |
dc.contributor.other | University of Oxford | - |
dc.contributor.other | Kumamoto Daigaku | - |
dc.contributor.other | Consorci Sanitari de Terrassa | - |
dc.contributor.other | Universitat de Vic-Universitat Central de Catalunya (UVic-UCC) | - |
dc.contributor.other | Institució Catalana de Recerca i Estudis Avançats (ICREA) | - |
dc.contributor.other | Instituto de Salud Carlos III | - |
dc.contributor.other | Universitat Autònoma de Barcelona (UAB) | - |
dc.date.accessioned | 2022-09-09T07:32:28Z | - |
dc.date.available | 2022-09-09T07:32:28Z | - |
dc.date.issued | 2022-03-01 | - |
dc.identifier.citation | Muñoz-Moreno, J.A., Carrillo-Molina, S., Martínez-Zalacaín, I., Miranda, C., Manzardo, C., Coll, P., Meulbroek, M., Hanke, T., Garolera, M., Miró, J.M., Brander, C., Clotet, B., Soriano-Mas, C., Moltó, J. & Mothe, B. (2022). Preserved central nervous system functioning after use of romidepsin as a latency-reversing agent in an HIV cure strategy. AIDS, 36(3), 363-372. doi: 10.1097/QAD.0000000000003121 | - |
dc.identifier.issn | 0269-9370MIAR | - |
dc.identifier.uri | http://hdl.handle.net/10609/146755 | - |
dc.description.abstract | Objective: To assess the central nervous system (CNS) impact of a kick&kill HIV cure strategy using therapeutic vaccine MVA.HIVconsv and the histone deacetylase inhibitor (HDACi) romidepsin (RMD) as latency-reversing agent. Design: Neurological observational substudy of the BCN02 trial (NCT02616874), a proof-of-concept, open-label, single-arm, phase I clinical trial testing the safety and immunogenicity of the MVA.HIVconsv vaccine and RMD in early-treated HIV-1-infected individuals. A monitored antiretroviral pause (MAP) was performed, with cART resumption after 2 pVL more than 2000 copies/ml. Reinitiated participants were followed for 24 weeks. Methods: Substudy participation was offered to all BCN02 participants (N = 15). Evaluations covered cognitive, functional, and brain imaging outcomes, performed before RMD administration (pre-RMD), after three RMD infusions (post-RMD), and at the end of the study (EoS). A group of early-treated HIV-1-infected individuals with matched clinical characteristics was additionally recruited (n = 10). Primary endpoint was change in a global cognitive score (NPZ-6). Results: Eleven participants from BCN02 trial were enrolled. No significant changes were observed in cognitive, functional, or brain imaging outcomes from pre-RMD to post-RMD. No relevant alterations were detected from pre-RMD to EoS either. Scores at EoS were similar in participants off cART for 32 weeks (n = 3) and those who resumed therapy for 24 weeks (n = 7). Controls showed comparable punctuations in NPZ-6 across all timepoints. Conclusion: No detrimental effects on cognitive status, functional outcomes, or brain imaging parameters were observed after using the HDACi RMD as latency-reversing agent with the MVA.HIVconsv vaccine in early-treated HIV-1-infected individuals. CNS safety was also confirmed after completion of the MAP. | en |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | ca |
dc.publisher | AIDS | ca |
dc.relation.ispartof | AIDS, 2022, 36(3) | - |
dc.relation.ispartofseries | 36;3 | - |
dc.relation.uri | http://doi.org/10.1097/QAD.0000000000003121 | - |
dc.rights | CC BY-ND 4.0 | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nd/4.0 | - |
dc.rights.uri | NO | - |
dc.subject | central nervous system | en |
dc.subject | histone deacetylase inhibitors | en |
dc.subject | HIV infection | en |
dc.subject | kick&kill strategies | en |
dc.subject | MVA.HIVconsv | en |
dc.subject | romidepsin | en |
dc.subject | sistema nervioso central | es |
dc.subject | inhibidores de histona desacetilasa | es |
dc.subject | infección por VIH | es |
dc.subject | estrategias kick & kil | es |
dc.subject | MVA.HIVconsv | es |
dc.subject | romidepsina | es |
dc.subject | sistema nerviós central | ca |
dc.subject | inhibidors de la histona deacetilasa | ca |
dc.subject | infecció pel VIH | ca |
dc.subject | estratègies kick&kill | ca |
dc.subject | MVA.HIVconsv | ca |
dc.subject | romidepsina | ca |
dc.subject.lcsh | central nervous system | en |
dc.title | Preserved central nervous system functioning after use of romidepsin as a latency-reversing agent in an HIV cure strategy | ca |
dc.type | info:eu-repo/semantics/article | ca |
dc.subject.lemac | sistema nerviós central | ca |
dc.subject.lcshes | sistema nervioso central | es |
dc.rights.accessRights | info:eu-repo/semantics/embargoedAccess | - |
dc.identifier.doi | http://doi.org/10.1097/QAD.0000000000003121 | - |
dc.gir.id | AR/0000009506 | - |
dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/PI15-01188 | - |
dc.relation.projectID | info:eu-repo/grantAgreement/UK/G0701669 | - |
dc.relation.projectID | info:eu-repo/grantAgreement/UK/G1001757 | - |
dc.relation.projectID | info:eu-repo/grantAgreement/UK/MR-N023668-1 | - |
dc.type.version | info:eu-repo/semantics/acceptedVersion | - |
dc.date.embargoEndDate | 2023-03-01 | - |
Aparece en las colecciones: | Articles Articles cientÍfics |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
muñoz_aids_preserved.pdf | 343,72 kB | Adobe PDF | Visualizar/Abrir |
Comparte:
Los ítems del Repositorio están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.